To view the fulltext, please log in
To view the pdf, please log in
The main purpose of using diuretics is usually lost sight of, i.e. it is for the relief of dyspnea by using the least amount of a diuretic. The production of a low output state and hypercoagulation in an attempt to achieve dry weight by lowering blood volume excessively are among the hazards of using more diuretic than is absolutely necessary to achieve the goal of relieving dyspnea. The use of jugular venous pressure measurement and the status of dyspnea should have precedence over body weight in determining diuretic dose adjustment. Often forgotten in using diuretics is that potassium without magnesium will not enter cells and that the almost universal preference for furosemide over thiazides threatens to increase the incidence of osteoporosis. Also, the tendency to ignore loss of the water-soluble vitamins thiamine and ascorbic acid may result in refractory edema and the inability to manage the stresses of congestive heart failure.
Copyright © 2000 S. Karger AG, Basel
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Nicholls MG, Espiner EA, Hughes H, Rogers T: Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. Br Heart J 1976;38:1025–1030.
- Capasso G, Pica A, Saviano C: Clinical complications of diuretic therapy. Kidney Int 1997;51:516–520.
- Suki WN: Acute treatment of hypercalcemia with furosemide. N Engl J Med 1970;283:836–840.
- Norenberg DD: Furosemide, hypertension, and osteoporosis. JAMA 1979;241:237–238.
- Cauley JA, Cummings SR, Seeley DG, Black D, Browner W, Kuller LH, Nevitt MC: Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med 1993;118:666–671.
- Sonnenblick M, Friedlander Y, Rosin AJ: Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993;103:601–605.
- Stern N, Lee D, Silis V: The effects of high calcium intake on blood pressure. Hypertension 1984;6:639–646.
- Zemel MB, Gualdoni SM, Sowers JR: Sodium excretion and plasma renin activity in normotensive and hypertensive black adults. J Hypertens 1986;4(suppl 6):5343–5345.
- Zemel MB, Gualdoni SM Sowers JR: Reductions in total and extracellular water associated with calcium-induced natriuresis and the antihypertensive effect of calcium in blacks. Am J Hypertens 1988;1:70–72.
- Chan WC, Ikram H, Espiner EA: The acute effects of furosemide on the haemodynamics and the renin-angiotensin-aldosterone system of patients with congestive heart failure (abstract 1252). Tokyo World Congress of Cardiology, 1978.
- Goodman LS, Gilman A: The Pharmacological Basis of Therapeutics, ed 9. New York, McGraw-Hill, 1996, p 70.
- Forrester TM, Shirrffs: Comparative studies of furosemide, mersalyl, and chlorothiazide. Scott Med J 1967;12:13–20.
- Sanders JG, Gillis OS, Marketto DL Jr, Gready TG Jr: Chlorthalidone in edema of pregnancy. NY State J Med 1955;65:762–764.
- Constant J: Bedside Cardiology, ed 5. Philadelphia, Lippincott, Williams & Wilkins, 1999, chap 4.
- Breckenridge A, Dollery CT, Welborn TA, Fraser R: Glucose tolerance in hypertensive patients on long-term diuretic therapy. Lancet 1967;i:61–64.
- Sheridan DJ, Terry G, Tynan MJ: Allopurinol – An agent for myocardial protection during hypoxia. Cardiovasc Med 1978;3:1207–1210.
- Shimon I, Aomog S, Vered Z, Seligmann H, Shefi M, Peleg E, Rosenthal T, Motro M, Halkin H, Ezra D: Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 1995;98:485–489.
- Burch GE, Walsh JJ: Cardiac insufficiency in chronic alcoholism. Am J Cardiol 1960;6:864–874.
- Banhidi ZG: Thiamine-sparing action of ascorbic acid. Ann NY Acad Sci 1961;92:324–328.
- King CG: Introductory remarks: The history and present status of vitamin C. Ann NY Acad Sci 1961;92:3–5.
- Baker EM: Vitamin C requirements in stress. Am J Clin Nutr 1967;20:583–590.
- Kallner A: Influence of vitamin C status on the urinary excretion of catecholamines in stress. Hum Nutr Clin Nutr 1983;37:405–411.
- Counsill JN, Hornig DH: Vitamin C. London, Applied Science, 1981, pp 370–371.
- Goldsmith GA: Human requirements for vitamin C. Ann NY Acad Sci 1961;92:230–245.
- Pirani CL: Review: Relation of vitamin C to adrenocortical function and stress phenomena. Metab Clin Exp 1952;1:197–222.
- Stone I: The Healing Factor: Vitamin C against Disease. New York, Grosset & Dunlap, 1972, p 101.
- Evans W: Vitamin C in heart failure. Lancet 1938;i:308–309.
- Belch JJF, Bridges AB, Scott N, Chopra M: Oxygen free radicals and congestive heart failure. Br Heart J 1991;65:245–248.
- Dhalla AK, Singh N, Singal PK: Antioxidant therapy associated with the reversal of oxidative stress delays the pathogenesis of heart failure. Abstracts of the 67th Scientific Session. 1994.
- Geranmayegan KM, Sole MJ: Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352–1356.
- Hornig B, Arakawa N, Kohler C, Drexler H: Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;97:363–368.
- Hinz B, Schroder H: Vitamin C attenuates nitrate tolerance independently of its antioxidant effect. FEBS Lett 1998;428/1–2:97–99.
- Burns JJ, Mosbach EH, Schulenberg S: Ascorbic acid synthesis in normal and drug-treated rats, studied with 1-ascorbic-114C acid. J Biol Chem 1954;207:679–687.
- Klenner FR: Observations on the dose and administration of ascorbic acid. J Appl Nutr 1971;23:61–88.